[{"address1": "1901 West 47th Place", "city": "Kansas City", "state": "KS", "zip": "66205", "country": "United States", "phone": "913 942 2300", "website": "https://www.cingulate.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.", "fullTimeEmployees": 13, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shane J. Schaffer Pharm.D.", "age": 49, "title": "CEO & Chairman of the Board", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 491961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Laurie A. Myers M.B.A., Ph.D.", "age": 67, "title": "Executive VP & COO", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 415167, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew N. Brams M.D.", "age": 60, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 244792, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer L. Callahan CPA", "age": 53, "title": "Senior VP, CFO & Secretary", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raul R. Silva M.D.", "age": 66, "title": "Executive VP & Chief Science Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Thomas  Dalton", "title": "Vice President of Investor & Public Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.67, "open": 4.8, "dayLow": 4.41, "dayHigh": 4.89, "regularMarketPreviousClose": 4.67, "regularMarketOpen": 4.8, "regularMarketDayLow": 4.41, "regularMarketDayHigh": 4.89, "forwardPE": -0.90348655, "volume": 82458, "regularMarketVolume": 82458, "averageVolume": 159437, "averageVolume10days": 146280, "averageDailyVolume10Day": 146280, "bid": 3.35, "ask": 5.72, "bidSize": 200, "askSize": 200, "marketCap": 14358667, "fiftyTwoWeekLow": 1.8, "fiftyTwoWeekHigh": 20.83, "fiftyDayAverage": 4.5846, "twoHundredDayAverage": 5.98122, "currency": "USD", "enterpriseValue": -1910336, "floatShares": 1761081, "sharesOutstanding": 3212230, "sharesShort": 152982, "sharesShortPriorMonth": 108411, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.0476, "heldPercentInsiders": 0.033, "heldPercentInstitutions": 0.01712, "shortRatio": 0.72, "shortPercentOfFloat": 0.0493, "impliedSharesOutstanding": 3212230, "bookValue": 6.815, "priceToBook": 0.6559061, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -16348455, "trailingEps": -43.22, "forwardEps": -7.31, "lastSplitFactor": "1:12", "lastSplitDate": 1723161600, "enterpriseToEbitda": 0.123, "52WeekChange": -0.6525298, "SandP52WeekChange": 0.21142256, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CING", "underlyingSymbol": "CING", "shortName": "Cingulate Inc.", "longName": "Cingulate Inc.", "firstTradeDateEpochUtc": 1638973800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "bf898f9d-c1c1-3f31-9c96-a5b2c0f73dcd", "messageBoardId": "finmb_1674914781", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.47, "targetHighPrice": 75.0, "targetLowPrice": 8.0, "targetMeanPrice": 35.4, "targetMedianPrice": 20.0, "recommendationMean": 1.75, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 10040149, "totalCashPerShare": 5.684, "ebitda": -15568522, "totalDebt": 234174, "quickRatio": 6.51, "currentRatio": 7.354, "debtToEquity": 1.945, "returnOnAssets": -1.04327, "returnOnEquity": -2.7381501, "grossProfits": -15493304, "freeCashflow": -10794803, "operatingCashflow": -16934228, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]